You have 9 free searches left this month | to do more

gb1211

Gb1211 is a drug used to treat Hepatic Impairment, Non-Small Cell Lung Cancer, Non-alcoholic Steatohepatitis (NASH), and other conditions. Gb1211 is being actively studied in 2 studies and prior, has been studied in 1.

Top SponsorsTop SitesTop Investigators
Galecto Biotech AB(For Parts A and B) Covance Clinical Research Unit Ltd
COAMC Medical
Diagnostic-Advisory center 'ALEKSANDROVSKA" Ltd
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects - 2019
Completed
Has Results
  • Safety and Tolerability
  • GB1211
  • Placebo
  • Leeds, United Kingdom
    (For Parts A and B) Covance Clinical Research Unit Ltd
2021-02-25
Feb 25, 2021
G
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
Not yet recruiting
  • Non-Small Cell Lung Cancer
  • GB1211
  • +2 more
  • (no location specified)
2022-02-14
Feb 14, 2022
G
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
Recruiting
  • Hepatic Impairment
  • GB1211
  • Placebo
  • Sofia, Bulgaria
  • +3 more
2022-02-14
Feb 14, 2022
G
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Withdrawn
  • Non-alcoholic Steatohepatitis (NASH)
  • GB1211
  • Placebo
  • (no location specified)
2021-02-02
Feb 2, 2021